$6.91
-0.17-2.33%
Last update: Nov 4, 4:39 PM
Immatics NV (IMTX) Stock Price, Quote, News & History
IMTXNASDAQ
Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the...
You can purchase shares of Immatics (NASDAQ:IMTX) through any online brokerage.
Other companies in Immatics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Immatics has a consensus price target of $18.00.
The stock price for Immatics (NASDAQ: IMTX) is $6.91 last updated November 4, 2026 at 4:39 PM EST.
There are no upcoming dividends for Immatics.
Immatics does not have any upcoming earnings scheduled.
There is no upcoming split for Immatics.
Immatics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with...
